Precigen (PGEN) to Release Earnings on Wednesday

Key Points

• Precigen will report Q1 2026 results before the market opens on May 13; analysts expect ($0.03) EPS and $20.807 million in revenue, with the earnings call at 4:00 PM ET.
• Director Randal J. Kirk sold 4,772,781 shares on March 30 for roughly $15.75 million, cutting his stake by about 94%, while insiders collectively own 47.10% of the company.
• Analyst coverage is mixed but averages a Hold rating and a $9.50 price target (four Buys, two Holds, one Sell), with several firms recently raising targets.

Precigen (NASDAQ:PGEN - Get Free Report) is expected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Precigen to post earnings of ($0.03) per share and revenue of $20.8070 million for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.09. Precigen had a negative net margin of 2,588.21% and a positive return on equity of 2,317.96%. The business had revenue of $4.57 million for the quarter, compared to analysts' expectations of $8.29 million. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Price Performance

PGEN stock opened at $4.33 on Wednesday. The company has a debt-to-equity ratio of 4.46, a quick ratio of 2.83 and a current ratio of 3.09. The firm has a 50 day moving average price of $3.77 and a 200-day moving average price of $4.06. Precigen has a 52-week low of $1.23 and a 52-week high of $5.47. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -3.23 and a beta of 1.07.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PGEN. Citizens Jmp raised their price objective on Precigen from $8.00 to $9.00 and gave the company a "market outperform" rating in a research report on Thursday, March 26th. Zacks Research raised Precigen from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Wall Street Zen raised Precigen from a "sell" rating to a "hold" rating in a research note on Saturday, March 28th. Weiss Ratings restated a "sell (d-)" rating on shares of Precigen in a report on Tuesday, April 21st. Finally, HC Wainwright lifted their price target on Precigen from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Thursday, March 26th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $9.50.

Insiders Place Their Bets

In related news, Director Randal J. Kirk sold 4,772,781 shares of the business's stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $3.30, for a total value of $15,750,177.30. Following the completion of the transaction, the director directly owned 302,213 shares in the company, valued at $997,302.90. The trade was a 94.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 47.10% of the stock is currently owned by insiders.

Institutional Trading of Precigen

Institutional investors and hedge funds have recently modified their holdings of the business. Xponance LLC lifted its holdings in shares of Precigen by 21.3% during the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company's stock worth $170,000 after buying an additional 2,993 shares in the last quarter. Intech Investment Management LLC raised its position in Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company's stock worth $263,000 after buying an additional 3,137 shares during the last quarter. HighTower Advisors LLC raised its position in Precigen by 4.2% in the 4th quarter. HighTower Advisors LLC now owns 104,560 shares of the biotechnology company's stock worth $437,000 after buying an additional 4,249 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Precigen by 10.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 56,006 shares of the biotechnology company's stock valued at $234,000 after acquiring an additional 5,222 shares during the period. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.